Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
8 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06952660 | Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | recruiting | Phase 4 | 100 | PfizerINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | recruiting | Phase 4 | 78 | TakedaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women |
| completed |
| Phase 4 |
| 82 |
| AbbVieINDUSTRY |
| 2 |
| Mar 31, 2022 |
| clinicaltrials |
| NCT04031885 | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | terminated | Phase 4 | 4 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 24, 2021 | clinicaltrials |
| NCT02092467 | Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis | completed | Phase 4 | 4,372 | PfizerINDUSTRY | 30 | Aug 17, 2021 | clinicaltrials |
| NCT03988114 | A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer(proMONARCH) | withdrawn | Phase 4 | 0 | Eli Lilly and CompanyINDUSTRY | 9 | Sep 6, 2019 | clinicaltrials |
| NCT00420927 | Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis(OPTIMA) | completed | Phase 4 | 1,032 | AbbottINDUSTRY | 21 | Apr 18, 2012 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials